Author： Dent Gordon
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.13, Iss.10, 2003-10, pp. : 1607-1617
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Asthma is a chronic inflammatory disease of the airways in which allergic mechanisms, involving antibodies of the IgE class, play an important role. A humanised anti-IgE antibody that prevents the binding of IgE to its receptors has proved effective in asthma in early clinical trials. Alternative strategies for the neutralisation or suppression of IgE are being investigated and some novel compounds and coadministration regimens have been suggested. These include the provocation of host anti-IgE immune responses and the suppression of IgE synthesis, as well as the blockade of IgE receptors. Although these routes of investigation are still at an early stage of exploration, they may produce some highly novel therapeutic agents.
Related content
Access to resources
Recommend
Anti-IgE Therapy in Allergic Asthma
Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 5, 2005-10 ,pp. :
IgE, Allergic Diseases, and Omalizumab
Current Pharmaceutical Design, Vol. 12, Iss. 30, 2006-10 ,pp. :
Anti-IgE monoclonal antibody E25 beneficial in allergic asthma
Inpharma, Vol. 1, Iss. 1220, 2000-01 ,pp. :